Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

被引:99
|
作者
Duffull, Stephen B. [1 ]
Wright, Daniel F. B. [1 ]
Winter, Helen R. [1 ,2 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9054, New Zealand
[2] Global Alliance TB Drug Dev, New York, NY 10005 USA
关键词
pharmacodynamics; pharmacokinetics; pharmacometrics; population analyses; statistical models; CYSTIC-FIBROSIS PATIENTS; DRUG DEVELOPMENT; DOSING STRATEGY; RENAL-FUNCTION; MODEL; ENOXAPARIN; PARAMETERS; DESIGN; ITRACONAZOLE; SIMULATION;
D O I
10.1111/j.1365-2125.2010.03891.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population analysis approach is an important tool for clinical pharmacology in aiding the dose individualization of medicines. However, due to their statistical complexity the clinical utility of population analyses is often overlooked. One of the key reasons to conduct a population analysis is to investigate the potential benefits of individualization of drug dosing based on patient characteristics (termed covariate identification). The purpose of this review is to provide a tool to interpret and extract information from publications that describe population analysis. The target audience is those readers who are aware of population analyses but have not conducted the technical aspects of an analysis themselves. Initially we introduce the general framework of population analysis and work through a simple example with visual plots. We then follow-up with specific details on how to interpret population analyses for the purpose of identifying covariates and how to interpret their likely importance for dose individualization.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [31] ENALAPRIL CLINICAL PHARMACOKINETICS AND PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS - AN OVERVIEW
    MACFADYEN, RJ
    MEREDITH, PA
    ELLIOTT, HL
    CLINICAL PHARMACOKINETICS, 1993, 25 (04) : 274 - 282
  • [32] Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation
    Saito, Tomohisa
    Iida, Satofumi
    Terao, Kimio
    Kumagai, Yuji
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12): : 1564 - 1572
  • [33] Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
    van Hasselt, J. G. C.
    Boekhout, A. H.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 126 - 132
  • [34] Pharmacokinetic-pharmacodynamic modeling:: Why?
    Pérez-Urizar, J
    Granados-Soto, V
    Flores-Murrieta, FJ
    Castañeda-Hernández, G
    ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (06) : 539 - 545
  • [35] Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
    Jamsen, Kris M.
    McLeay, Sarah C.
    Barras, Michael A.
    Green, Bruce
    CLINICAL PHARMACOKINETICS, 2014, 53 (02) : 111 - 122
  • [36] Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib
    Dunn, Allison
    Ditmarsch, Marc
    Kastelein, John J. P.
    Kling, Douglas
    Neild, Annie
    Davidson, Michael H.
    Gobburu, Joga
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (09): : 1150 - 1164
  • [37] Pharmacokinetic-pharmacodynamic relationships for analgesics
    Suri, A
    Estes, KS
    Geisslinger, G
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (08) : 307 - 323
  • [38] Population-based approach to the assessment of pharmacokinetic-pharmacodynamic data
    Troconiz, IF
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1996, 18 : 51 - 52
  • [39] A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients
    Mould, D
    Chapelsky, M
    Aluri, J
    Swagzdis, A
    Samuels, R
    Granett, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 210 - 222
  • [40] Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach
    Shu, Cathye
    Zhou, Honghui
    Afsharvand, Mehri
    Duan, Larry
    Zhang, Hui
    Noveck, Robert
    Raible, Donald
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (04): : 472 - 481